Science Corporation implants PRIMA chip in Stargardt patient
The PRIMA chip, developed for patients with Stargardt disease—an inherited form of vision loss—has been successfully implanted at Sydney Eye Hospital.
Science Corporation announced that it has successfully implanted its PRIMA vision-restoring chip in its first patient with Stargardt disease, an inherited condition that causes central vision loss.
First clinical application of the PRIMA chip
Science Corporation CEO Max Hodak announced that the company has successfully implanted its PRIMA vision-restoring chip into the first individual with Stargardt disease.
Stargardt disease and its effects
Stargardt disease is known as an inherited and incurable condition that slowly destroys central vision, affecting approximately 150,000 people worldwide.
Location of the operation
The company's first Stargardt patient underwent the procedure in May as part of an ongoing clinical trial at Sydney Eye Hospital in Australia.
Technical details of the intraocular implant
Placed at the back of the eye, the 2-millimeter chip works in conjunction with camera-equipped glasses to transmit a high-contrast black-and-white field of view.
Future plans
Science Corporation aims to develop next-generation implants with a larger field of view next year and ultimately target natural-level acuity in the future.